Uniting our global researchers for melanoma
28 October 2016
Melanoma Institute Australia (MIA) is bringing to Sydney some of the world’s leading melanoma researchers and clinicians today for the Australasian Melanoma Conference.
More than 380 researchers, clinicians, nurses and students are attending the two-day conference held at the Sofitel Wentworth in Sydney. The conference, hosted by MIA, is bringing together some of the greatest minds in melanoma research to showcase current practice and research innovation that will make a difference to the lives of melanoma patients.
MIA’s Associate Professor Robyn Saw, Chair of the Australasian Melanoma Conference, says this year’s event is an opportunity for physicians and researchers to learn about ground-breaking research and revolutionary melanoma treatment.
“The conference is a truly unique opportunity to build strong Australasian collaboration and to acquire information and knowledge to use in every day practice,” Associate Professor Saw says.
During the conference, MIA’s Associate Professor Jonathan Stretch AM is launching the new eBook Melanoma Principles & Practice, an interactive multi-touch e-textbook on melanoma care and treatment aimed at specialists.
Written and designed by MIA, the eBook is set to become an ultimate resource on melanoma, delivering specialists a seamless experience that supplements the text with interactive visual supports to build a multi-dimensional level of understanding that would not be possible from a printed book.
The Conference features a number of international keynote speakers. Dr Vernon Sondak from the Moffitt Cancer Center in the US is discussing melanoma in children and how to improve diagnosis and management, as well as communication with the young patient and their family.
Associate Professor Jennifer Wargo from MD Anderson Cancer Center is discussing her research on how gut flora – known as the microbiome – play a role in determining how well a patient responds to treatment.
“There is emerging evidence regarding the role of the microbiome in response to melanoma therapy, and it is quite likely that we will modify the microbiome to enhance responses to therapy in the upcoming months and years,” says Associate Professor Wargo.
Professor John Thompson AO from MIA is reporting on the new electronic clinical practice guidelines for the diagnosis and management of melanoma.
“Things are moving quickly in melanoma management. A comprehensive systematic review of the evidence was timely," Professor Thompson says. “Extensive use of the new guidelines will help to ensure that clinicians have access to the latest evidence-based recommendations when diagnosing and caring for people with melanoma."
More than 30 speakers are presenting at the Australasian Melanoma Conference, including a contingent of MIA experts such as Professor Richard Scolyer and Professor Georgina Long, as well as other eminent Australians in the field such as Professor Grant McArthur and Dr Mark Shackleton from the Peter MacCallum Cancer Centre.
Delegates are sharing insights and key learnings on social media throughout the day using the hashtag #MelanomaConf2016.
The Australasian Melanoma Conference is proudly sponsored by Bristol-Myers Squibb, MSD, Novartis, Sonic Healthcare, Amgen, Laverty Pathology and Pierre Fabre Australia.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
M4mWA is a life-changing ride to make a difference for the WA melanoma community.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play
This week, Melanoma Institute Australia hosted the first of six
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.